Patritumab plus Erlotinib in EGFR Wild-Type Advanced Non Small Cell Lung Cancer (NSCLC): Part a Results of HER3-Lung Study

被引：11

作者：

Paz-Arez, Luis ^{[1
]}

Serwatowski, Piotr ^{[2
]}

Szczesna, Aleksandra ^{[3
]}

Von Pawel, Joachim ^{[4
]}

Toschi, Luca ^{[5
]}

Tibor, Csoszi ^{[6
]}

Morabito, Alessandro ^{[7
]}

Zhang, Ling ^{[8
]}

Shuster, Dale ^{[8
]}

Chen, Shuquan ^{[9
]}

Copigneaux, Catherine ^{[9
]}

Akerley, Wallace ^{[10
]}

机构：

[1] Hosp Univ 12 Octubre, Madrid, Spain

[2] Hosp Univ 12 Octubre, Madrid, Poland

[3] Mazowieckie Ctr Leczenia Chorob Pluc I Gruzlicy, Otwock, Poland

[4] Asklepios Fachkliniken Munchen Gauting, Gauting, Germany

[5] IRCCS, Ist Clin Humanitas, Humanitas Canc Ctr, Milan, Italy

[6] Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz R, Szolnok, Hungary

[7] Thorac Ist Nazl Tumori Naples, Naples, Italy

[8] Dazichz Sankyo Inc, Edison, NJ USA

[9] Daiichi Sankyo Inc, Edison, NJ USA

[10] Huntsman Canc Inst, Salt Lake City, UT USA

来源：

关键词：

non-small cell lung cancer; Heregulin; Patritumab; Phase; 3;

D O I：

10.1016/j.jtho.2016.11.1712

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P3.02b-045

引用

页码：S1214 / S1215

页数：2